BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1
40 results:

  • 1. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
    Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
    Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma.
    Tabata M; Sato Y; Kogure Y; McClure MB; Oshikawa-Kumade Y; Saito Y; Shingaki S; Ito Y; Yuasa M; Koya J; Yoshida K; Kohno T; Miyama Y; Morikawa T; Chiba K; Okada A; Ogawa S; Ushiku T; Shiraishi Y; Kume H; Kataoka K
    Cell Rep; 2023 Jul; 42(7):112736. PubMed ID: 37405915
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The PROTAC selectively degrading Bcl-x
    Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
    Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
    [No Abstract]    [Full Text] [Related]  

  • 5. Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.
    Nian R; Jiang H; Zhao J; Hou W; Zhang H; Ma J; Lv P; Jiang L; Wang Y; Xu Y; Wu S; Lou J; Li W
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796015
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Design, Synthesis, and Evaluation of vhl-Based EZH2 Degraders to Enhance Therapeutic Activity against lymphoma.
    Tu Y; Sun Y; Qiao S; Luo Y; Liu P; Jiang ZX; Hu Y; Wang Z; Huang P; Wen S
    J Med Chem; 2021 Jul; 64(14):10167-10184. PubMed ID: 34196564
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical
    Weidle UH; Nopora A
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):349-368. PubMed ID: 33994361
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.
    Wu D; Dasgupta A; Read AD; Bentley RET; Motamed M; Chen KH; Al-Qazazi R; Mewburn JD; Dunham-Snary KJ; Alizadeh E; Tian L; Archer SL
    Free Radic Biol Med; 2021 Jul; 170():150-178. PubMed ID: 33450375
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
    He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
    Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Curcumin Inhibits the Proliferation, Migration, Invasion, and Apoptosis of Diffuse Large B-Cell lymphoma Cell Line by Regulating MiR-21/vhl Axis.
    Chen L; Zhan CZ; Wang T; You H; Yao R
    Yonsei Med J; 2020 Jan; 61(1):20-29. PubMed ID: 31887796
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
    Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
    Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Nutritional status at diagnosis of cancer in children and adolescents in Guatemala and its relationship to socioeconomic disadvantage: A retrospective cohort study.
    Villanueva G; Blanco J; Rivas S; Molina AL; Lopez N; Fuentes AL; Muller L; Caceres A; Antillon F; Ladas E; Barr RD
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27647. PubMed ID: 30729661
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict lymphoma Occurrence in Patients With Primary Sjögren's Syndrome.
    Sène D; Ismael S; Forien M; Charlotte F; Kaci R; Cacoub P; Diallo A; Dieudé P; Lioté F
    Arthritis Rheumatol; 2018 Sep; 70(9):1481-1488. PubMed ID: 29669392
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. ALK-TPM3 rearrangement in adult renal cell carcinoma: Report of a new case showing loss of chromosome 3 and literature review.
    Bodokh Y; Ambrosetti D; Kubiniek V; Tibi B; Durand M; Amiel J; Pertuit M; Barlier A; Pedeutour F
    Cancer Genet; 2018 Feb; 221():31-37. PubMed ID: 29405994
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
    Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
    Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.